ORR

IDEAYA Biosciences and Hengrui Pharma presented Phase 1 trial data for IDE849 (SHR-4849), a DLL3-targeting TOP1 ADC, in advanced Small Cell Lung Cancer (SCLC). Across all SCLC lines, the Overall Response Rate (ORR) was 73.2% with a median Progression-Free Survival (PFS) of 6.7 months. In 2nd-line SCLC, the ORR was 77.1%, with median PFS not reached. Notably, patients with brain metastases showed a confirmed ORR of 66.7%. The safety profile was manageable. This data suggests IDE849 has a potential best-in-class profile and warrants further clinical development.